Appeal No. 1999-1280
Application No. 08/379,813
Claims 1 and 6 are representative of the claims on appeal and read as follows:
1. A method for treatment of a supraalveolar periodontal lesion or defect
consisting essentially of administering to a site of said supraalveolar
periodontal lesion or defect a pharmaceutically acceptable composition
containing one or more purified or recombinant bone morphogenetic
protein (BMPs) in an amount sufficient to cause regeneration of alveolar
bone at the site of said lesion or defect in both a vertical and horizontal
direction.
6. A method for treatment of a supraalveolar periodontal lesion or defect
according to claim 1, wherein the composition comprises recombinant
human BMP-12 and recombinant human BMP-2 in a suitable carrier.
The references relied on by the examiner are:
Antoniades et al. (Antoniades) 5,124,316 Jun. 23, 1992
Bentz et al. (Bentz) 5,393,739 Feb. 28, 1995
GROUNDS OF REJECTION
Claims 1-33 stand rejected under 35 U.S.C. § 112, first paragraph, as the
specification fails to provide an enabling description of all Bone Morphogenetic Proteins
(BMPs).1
Claims 1, 2, 7-13, 18-24, and 29-33 stand rejected under 35 U.S.C. § 102 as
being anticipated by Antoniades.
Claims 1-33 stand rejected under 35 U.S.C. § 103 as being unpatentable over
Bentz.
1 We note the rejection of claims 1-33 is directly connected and relates to the objection
to the specification. In re Hengehold, 440 F.2d 1395, 1403-1404, 169 USPQ 473, 479-
480 (CCPA 1971).
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: November 3, 2007